Presentation is loading. Please wait.

Presentation is loading. Please wait.

Non-Invasive Liver Testing

Similar presentations


Presentation on theme: "Non-Invasive Liver Testing"— Presentation transcript:

1 Non-Invasive Liver Testing

2 Non-invasive Liver Stiffness Testing
Assessing The Liver’s Mechanical Properties Stiffness Elasticity

3 FibroScan Operating Principle
Vibration Controlled Transient Elastography VCTE™

4 VCTE Measurement Steps
Mechanically induce a shear wave Measure shear wave speed Calculate stiffness

5 Mechanical Shear Wave Induction
5

6 Mechanical Shear Wave Induction
50 Hz Shear Wave 6

7 Shear Wave Speed Correlates to Stiffness
Low speed = Low Stiffness High speed = High Stiffness

8 Shear Wave Speed Measurement
Pulse Echo Ultrasound Ultrasound Pulse Shear Wave Ultrasound Echo

9 Shear Wave Speed Measurement
Pulse Echo Ultrasound Shear Wave Speed Measurement Shear Wave Ultrasound Pulse Ultrasound Echo

10 Mathematical Reconstruction of Shear Wave Propagation
25 mm Time 65 mm Propagation Map Mathematical Reconstruction of Shear Wave Propagation Subcutaneous Tissue Liver Tissue Explored Region

11 Propagation Map Shear Wave Passes 25 mm Liver Tissue Time 25 mm 65 mm
Subcutaneous Tissue Liver Tissue Shear Wave Passes 25 mm

12 Propagation Map Shear Wave Passes 65 mm Liver Tissue Time 25 mm 65 mm
Subcutaneous Tissue Liver Tissue Shear Wave Passes 65 mm

13 Propagation Map Shear Wave Speed = D/T Liver Tissue Time 25 mm 65 mm
Subcutaneous Tissue Liver Tissue Shear Wave Speed = D/T 40 mm Time ?

14 Stiffness Calculation Formula
Measure Calculate Shear Wave Speed Vs (m/s) Equivalent Stiffness E (kPa) E = 3pVS2 Elasticity (Stiffness) Liver Tissue Density Velocity of Shear Wave

15 Shear Wave Speed Examples
Slow Fast Depth Depth Time

16 Primary FibroScan Applications
Assess urgency of need for care Guide DAA duration Longitudinal testing Disease progression Disease progression rate Therapeutic response

17 VCTE Cutoff Value References

18 Multiple Disease Groups
FibroScan Cutoff Value Reference Multiple Disease Groups F3 F4 Disease F0-F1 F2 Significant Fibrosis Cirrhosis HBV < 6.0 > 6.0 > 9.0 > 12.0 HCV < 7.0 > 7.0 > 9.5 HCV-HIV < 10.0 > 11.0 > 14.0 Cholestatic > 7.5 > 10.0 > 17.0 NAFLD/NASH Utilization of FibroScan in Clinical Practice; Bonder et al, Current Gastroenterology Rep,

19 Multiple Disease Groups
FibroScan Cutoff Value Reference Multiple Disease Groups F3 F4 Disease F0-F1 F2 Significant Fibrosis Cirrhosis HBV < 6.0 > 6.0 > 9.0 > 12.0 HCV < 7.0 > 7.0 > 9.5 HCV-HIV < 10.0 > 11.0 > 14.0 Cholestatic > 7.5 > 10.0 > 17.0 NAFLD/NASH Utilization of FibroScan in Clinical Practice; Bonder et al, Current Gastroenterology Rep,

20 VCTE Accuracy Validation Meta-Analysis
VCTE Versus Biopsy Staged Fibrosis # Studies # Patients ETIOLOGY Diagnosis of significant fibrosis AUROC F≥F3 Diagnosis of cirrhosis AUROC F4 REFERENCE 4 546 HCV 0.83 0.95 [1] 9 2083 Multiple 0.87 0.96 [2] 38 8433 0.84 0.94 [3] Accuracy of FibroScan, Compared to Histology, in Analysis of Liver Fibrosis in Patients with HBV or HCV; A United States Multicenter Study; Clinical Gastroenterology & Hepatology 2015

21 VCTE Accuracy Validation Meta-Analysis
VCTE Versus Biopsy Staged Fibrosis # Studies # Patients ETIOLOGY Diagnosis of significant fibrosis AUROC F≥F3 Diagnosis of cirrhosis AUROC F4 REFERENCE 4 546 HCV 0.83 0.95 [1] 9 2083 Multiple 0.87 0.96 [2] 38 8433 0.84 0.94 [3] Accuracy of FibroScan, Compared to Histology, in Analysis of Liver Fibrosis in Patients with HBV or HCV; A United States Multicenter Study; Clinical Gastroenterology & Hepatology 2015

22 Liver Stiffness Influencers
Fibrosis Hepatic Blood Pressure 3 Hepatic Pressure Alcohol 2 Hepatic Inflammation 1 Alanine aminotransferase-based Algorithms of Liver Stiffness Measurement by Transient Elastography (FibroScan) for Liver Fibrosis in Chronic Hepatitis B; Chan et al; Journal of Viral Hepatitis, 2009, 16, 36–44 Effect of Alcohol on Liver Stiffness Measured by Transient Elastography; Bardou-Jacquet et al; World Journal of Gastroenterology, Jan 28, 19(4); Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension; Berzigotti, A., et al; PLOS One, 2013. 8(3): p. e58742

23 Meal Restriction Recommendation
Fast > 3 hours prior to testing Drinking water is acceptable Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection; Mederacke, I., et al; Liver International, 2009. 29(10): p Liver Stiffness Is Influenced by a Standardized Meal in Patients With Chronic Hepatitis C Virus at Different Stages of Fibrotic Evolution; Arena et al; Hepatology, Volume 58, No 1, 2013

24 DAA Prequalification in HCV
27/04/2017 DAA Prequalification in HCV Low Significant Fibrosis Cirrhosis Stiffness Low Significant Fibrosis Cirrhosis Stiffness Significant Fibrosis Cirrhosis Stiffness DAA Qualified ? Utilization of FibroScan Testing in Hepatitis C Virus Management; Gastroenterology & Hepatology Volume 11, Issue 3, March 2015 January 6, 2010

25 DAA Prequalification in HCV
27/04/2017 DAA Prequalification in HCV Low Significant Fibrosis Cirrhosis Stiffness Low Significant Fibrosis Cirrhosis Stiffness Significant Fibrosis Cirrhosis Stiffness DAA 12 Weeks Utilization of FibroScan Testing in Hepatitis C Virus Management; Gastroenterology & Hepatology Volume 11, Issue 3, March 2015 January 6, 2010

26 DAA Prequalification in HCV
27/04/2017 DAA Prequalification in HCV Low Significant Fibrosis Cirrhosis Stiffness Low Significant Fibrosis Cirrhosis Stiffness Significant Fibrosis Stiffness DAA 24 Weeks Utilization of FibroScan Testing in Hepatitis C Virus Management; Gastroenterology & Hepatology Volume 11, Issue 3, March 2015 January 6, 2010

27 Practice Guideline Overview FibroScan VCTE Listings
Society Region Disease Guidance AASLD / IDSA1 USA HCV First line test WHO2 World HCV & HBV EASL3 Europe NICE4 UK HBV Recommendations for Testing, Managing and Treating Hepatitis C; When & In Whom to Initiate Antiviral Therapy, AASLD & IDSA Practice Guidelines; 2. WHO Guidelines for Screening, Care and Treatment of Persons with Hepatitis C Infection; ISBN 3. EASL Clinical Practice Guidelines : Noninvasive Tests for Evaluation of Liver Disease Severity and Prognosis; Journal of Hepatology 2015 4. Diagnosis and Management of Chronic Hepatitis B in Children, Young People & Adults; guidance.nice.org.uk/cg165

28 Report Review

29

30 FibroScan Operating Principle
Controlled Attenuation Parameter CAP™

31 Ultrasound Attenuation Rate
CAP Liver Assessment Ultrasound Attenuation Rate Unit: dB/M (decibels per meter)

32 Ultrasound Attenuation Rate Example
Signal Intensity 75 % 50 % 25 % 0 % 50 mm 40 mm 30 mm Depth Below Skin

33 Ultrasound Attenuation Normal Liver Tissue
Low Attenuation Rate

34 Ultrasound Attenuation Fatty Liver Tissue
High Attenuation Rate

35 Ultrasound Attenuation Rate Steatosis Correlate
Low attenuation rate = Low Steatosis High attenuation rate = High Steatosis

36 CAP Value VCTE Value

37 Echosens North America, Inc
Slide Deck Complements of: Echosens North America, Inc 185 Alewife Brook Parkway Suite 410 Cambridge MA 02138


Download ppt "Non-Invasive Liver Testing"

Similar presentations


Ads by Google